Top-line data suggested the randomized, double-blind, placebo-controlled phase II trial of Idera Pharmaceuticals Inc.’s lead candidate IMO-8400 met its primary endpoint, demonstrating the compound was safe and well tolerated in patients with moderate-to-severe plaque psoriasis.